financetom
Business
financetom
/
Business
/
Medical aesthetics platform So-Young International's Q3 revenue up 4% on center expansion
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Medical aesthetics platform So-Young International's Q3 revenue up 4% on center expansion
Nov 17, 2025 2:38 AM

Overview

* So-Young ( SY ) Q3 revenue rises 4% yr/yr to RMB386.7 mln ($54.3 million), driven by center expansion

* Company reports Q3 net loss of RMB64.3 mln, compared to net income last year

* Verified treatment visits and aesthetic treatments performed increased significantly

Outlook

* Company expects Q4 2025 aesthetic treatment services revenue between RMB216 mln and RMB226 mln

Result Drivers

* CENTER EXPANSION - Revenue growth driven by expansion of branded aesthetic centers

* TREATMENT SERVICES GROWTH - Aesthetic treatment services revenue surged 304.6% due to center expansion

* USER ENGAGEMENT - Verified treatment visits and aesthetic treatments performed increased significantly

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 RMB

Revenue 386.67

mln

Q3 Net -RMB

Income 64.84

mln

Q3 Gross RMB

Profit 182.87

mln

Q3 -RMB

Operatin 255.58

g mln

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the online services peer group is "buy."

* Wall Street's median 12-month price target for So-Young International Inc ( SY ) is $7.89, about 53.5% above its November 14 closing price of $3.67

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Sanara MedTech Q1 Net Loss Widens, Revenue Increases -- Shares Down
Sanara MedTech Q1 Net Loss Widens, Revenue Increases -- Shares Down
May 13, 2024
01:49 PM EDT, 05/13/2024 (MT Newswires) -- Sanara MedTech ( SMTI ) reported Q1 net loss Monday of $0.21 per diluted share, widening from $0.14 a year earlier. One analyst polled by Capital IQ expected a loss of $0.07. Revenue for the quarter ended March 31 was $18.5 million, up from 15.5 million a year earlier. One analyst surveyed by...
--Street Color: Kraft Heinz Reportedly Mulls Sale of Oscar Mayer
--Street Color: Kraft Heinz Reportedly Mulls Sale of Oscar Mayer
May 13, 2024
01:50 PM EDT, 05/13/2024 (MT Newswires) -- (Street Color news is derived from real time discussions with market professionals globally subscribed to the Street Color Premium Chat service on Bloomberg IB Chat and the ICE IM. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.) Price: 36.45, Change: +0.21, Percent...
Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday?
Why Is Small-Cap Alzheimer's-Focused AC Immune Stock Trading Higher On Monday?
May 13, 2024
Monday, Takeda Pharmaceutical Company Limited ( TAK ) and AC Immune SA ( ACIU ) announced an exclusive, worldwide option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24.060 for Alzheimer’s disease. ACI-24.060 is an anti-Abeta active immunotherapy candidate designed to induce an antibody response against the toxic forms of Abeta believed to drive plaque formation and Alzheimer’s...
Why MiNK Therapeutics Stock Is Up 11% Monday
Why MiNK Therapeutics Stock Is Up 11% Monday
May 13, 2024
MiNK Therapeutics, Inc. ( INKT ) shares are trading higher Monday after the clinical-stage biopharmaceutical company announced private placement financing of $5.8 million. What Happened: On Monday, MiNK Therapeutics ( INKT ) entered into a stock purchase agreement to sell securities in a private investment in public equity (PIPE) agreement. MiNK said it will sell 4.64 million shares at a price...
Copyright 2023-2026 - www.financetom.com All Rights Reserved